Monoclonal Antibody Infusion for Cancer Therapy from Germany
Monoclonal antibody infusions such as rituximab are biotechnologically produced proteins that target specific cancer cells. These immunological products are directly involved in regulating immune processes, making them classifiable under tariff item 3002.90.00. They are prepared for therapeutic use in oncology.
Duty Rate — Germany → Canada
0%
Import Tips
• Ensure the product has a valid DIN from Health Canada
• Provide documentation of the biotechnological manufacturing process
• Check if a controlled substances permit is needed for certain active ingredients